332 related articles for article (PubMed ID: 29045079)
1. Improvements in health-related quality of life over 3 years with liraglutide 3.0 mg compared with placebo in participants with overweight or obesity.
Kolotkin RL; Gabriel Smolarz B; Meincke HH; Fujioka K
Clin Obes; 2018 Feb; 8(1):1-10. PubMed ID: 29045079
[TBL] [Abstract][Full Text] [Related]
2. Improvements in health-related quality of life with liraglutide 3.0 mg compared with placebo in weight management.
Kolotkin RL; Fujioka K; Wolden ML; Brett JH; Bjorner JB
Clin Obes; 2016 Aug; 6(4):233-42. PubMed ID: 27198973
[TBL] [Abstract][Full Text] [Related]
3. Health-related quality of life in two randomized controlled trials of phentermine/topiramate for obesity: What mediates improvement?
Kolotkin RL; Gadde KM; Peterson CA; Crosby RD
Qual Life Res; 2016 May; 25(5):1237-44. PubMed ID: 26446094
[TBL] [Abstract][Full Text] [Related]
4. Health-related quality of life in randomized controlled trials of lorcaserin for obesity management: what mediates improvement?
Kolotkin RL; Crosby RD; Wang Z
Clin Obes; 2017 Dec; 7(6):347-353. PubMed ID: 28815987
[TBL] [Abstract][Full Text] [Related]
5. Patient-reported quality of life in a randomized placebo-controlled trial of naltrexone/bupropion for obesity.
Kolotkin RL; Chen S; Klassen P; Gilder K; Greenway FL
Clin Obes; 2015 Oct; 5(5):237-44. PubMed ID: 26222044
[TBL] [Abstract][Full Text] [Related]
6. The relationship between health-related quality of life and weight loss.
Kolotkin RL; Crosby RD; Williams GR; Hartley GG; Nicol S
Obes Res; 2001 Sep; 9(9):564-71. PubMed ID: 11557837
[TBL] [Abstract][Full Text] [Related]
7. Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials.
O'Neil PM; Aroda VR; Astrup A; Kushner R; Lau DCW; Wadden TA; Brett J; Cancino AP; Wilding JPH;
Diabetes Obes Metab; 2017 Nov; 19(11):1529-1536. PubMed ID: 28386912
[TBL] [Abstract][Full Text] [Related]
8. Changes in health-related quality of life with intensive behavioural therapy combined with liraglutide 3.0 mg per day.
Chao AM; Wadden TA; Walsh OA; Gruber KA; Alamuddin N; Berkowitz RI; Tronieri JS
Clin Obes; 2019 Dec; 9(6):e12340. PubMed ID: 31691531
[TBL] [Abstract][Full Text] [Related]
9. 12-year trajectory of health-related quality of life in gastric bypass patients versus comparison groups.
Kolotkin RL; Kim J; Davidson LE; Crosby RD; Hunt SC; Adams TD
Surg Obes Relat Dis; 2018 Sep; 14(9):1359-1365. PubMed ID: 29884519
[TBL] [Abstract][Full Text] [Related]
10. Effect of semaglutide 2.4 mg on physical functioning and weight- and health-related quality of life in adults with overweight or obesity: Patient-reported outcomes from the STEP 1-4 trials.
Rubino D; Bjorner JB; Rathor N; Sharma AM; von Huth Smith L; Wharton S; Wadden T; Zeuthen N; Kolotkin RL
Diabetes Obes Metab; 2024 Jul; 26(7):2945-2955. PubMed ID: 38698650
[TBL] [Abstract][Full Text] [Related]
11. Psychometric evaluation of the impact of weight on quality of life-lite questionnaire (IWQOL-lite) in a community sample.
Kolotkin RL; Crosby RD
Qual Life Res; 2002 Mar; 11(2):157-71. PubMed ID: 12018739
[TBL] [Abstract][Full Text] [Related]
12. One-year health-related quality of life outcomes in weight loss trial participants: comparison of three measures.
Kolotkin RL; Norquist JM; Crosby RD; Suryawanshi S; Teixeira PJ; Heymsfield SB; Erondu N; Nguyen AM
Health Qual Life Outcomes; 2009 Jun; 7():53. PubMed ID: 19505338
[TBL] [Abstract][Full Text] [Related]
13. Improvement of Health-Related Quality of Life After Roux-en-Y Gastric Bypass Related to Weight Loss.
Monpellier VM; Antoniou EE; Aarts EO; Janssen IMC; Jansen ATM
Obes Surg; 2017 May; 27(5):1168-1173. PubMed ID: 27896646
[TBL] [Abstract][Full Text] [Related]
14. Estimating a preference-based single index for the Impact of Weight on Quality of Life-Lite (IWQOL-Lite) instrument from the SF-6D.
Brazier JE; Kolotkin RL; Crosby RD; Williams GR
Value Health; 2004; 7(4):490-8. PubMed ID: 15449641
[TBL] [Abstract][Full Text] [Related]
15. Exposure-response analyses of liraglutide 3.0 mg for weight management.
Wilding JP; Overgaard RV; Jacobsen LV; Jensen CB; le Roux CW
Diabetes Obes Metab; 2016 May; 18(5):491-9. PubMed ID: 26833744
[TBL] [Abstract][Full Text] [Related]
16. Effect of moderate weight loss on health-related quality of life: an analysis of combined data from 4 randomized trials of sibutramine vs placebo.
Samsa GP; Kolotkin RL; Williams GR; Nguyen MH; Mendel CM
Am J Manag Care; 2001 Sep; 7(9):875-83. PubMed ID: 11570021
[TBL] [Abstract][Full Text] [Related]
17. Impact of weight change on quality of life in adults with overweight/obesity in the United States: a systematic review.
Kroes M; Osei-Assibey G; Baker-Searle R; Huang J
Curr Med Res Opin; 2016; 32(3):485-508. PubMed ID: 26652030
[TBL] [Abstract][Full Text] [Related]
18. Validation of a new measure of quality of life in obesity trials: Impact of Weight on Quality of Life-Lite Clinical Trials Version.
Kolotkin RL; Williams VSL; Ervin CM; Williams N; Meincke HH; Qin S; von Huth Smith L; Fehnel SE
Clin Obes; 2019 Jun; 9(3):e12310. PubMed ID: 30993900
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
Davies MJ; Bergenstal R; Bode B; Kushner RF; Lewin A; Skjøth TV; Andreasen AH; Jensen CB; DeFronzo RA;
JAMA; 2015 Aug; 314(7):687-99. PubMed ID: 26284720
[TBL] [Abstract][Full Text] [Related]
20. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study.
Wadden TA; Hollander P; Klein S; Niswender K; Woo V; Hale PM; Aronne L;
Int J Obes (Lond); 2013 Nov; 37(11):1443-51. PubMed ID: 23812094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
